

## Supporting Information

### Rh(III)-catalyzed Synthesis of Pyrazolo[1,2-*a*]cinnolines from Pyrazolidinones and Diazo compounds

Panpan Li, Xiaoying Xu, Jiayi Chen, Hequan Yao\* and Aijun Lin\*

*State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,  
China Pharmaceutical University, Nanjing 210009, P. R. China.*

*Nanjing, 210009, P. R. China.*

E-mail: ajlin@cpu.edu.cn, hyao@cpu.edu.cn

## CONTENT

1. General Information .....	2
2. General Procedure for the Preparation of Starting Materials .....	2
2.1 Preparation of 1-arylpyrazolidin-3-ones.....	2
2.2 Preparation of Diazo Substrates .....	3
3. Experimental Procedures .....	3
3.1 General Procedures.....	3
3.2 Additional Condition Screening .....	4
4. Characterization of the Titled Products.....	6
5. Gram-scale Experiment and Further Transformations of Pyrazolo[1,2- <i>a</i> ]cinnoline <b>3aa</b> .....	13
5.1 A gram scale experiment of <b>3aa</b> .....	13
5.2 Further Transformations of <b>3aa</b> .....	13
6. Mechanistic Experiments .....	15
6.1 Competitive Reaction .....	15
6.2 H/D exchange experiment .....	16
6.3 kinetic isotope effect.....	17
7. Copies of $^1\text{H}$ NMR and $^{13}\text{C}$ NMR Spectra of the Titled Compounds .....	18
8. HMBC analysis.....	48

## 1. General Information

**Reagents and Solvents:** PE refers to petroleum ether b.p. 60-90 °C, EA refers to ethyl acetate, DCM refers to methylene dichloride and DCE refers to 1,2-dichloroethane. All other starting materials and solvents were commercially available and were used without further purification unless otherwise stated.


**Chromatography:** Flash column chromatography was carried out using commercially available 200-300 mesh under pressure unless otherwise indicated. Gradient flash chromatography was conducted eluting with PE/EA, they are listed as volume/volume ratios.

**Data collection:**  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were collected on BRUKER AV-300 (300 MHz) spectrometer using  $\text{CDCl}_3$  as solvent. Chemical shifts of  $^1\text{H}$  NMR were recorded in parts per million (ppm,  $\delta$ ) relative to tetramethylsilane ( $\delta = 0.00$  ppm) with the solvent resonance as an internal standard ( $\text{CDCl}_3$ :  $\delta = 7.26$  ppm). Data are reported as follows: chemical shift in ppm ( $\delta$ ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), and integration. Chemical shifts of  $^{13}\text{C}$  NMR were reported in ppm with the solvent as the internal standard ( $\text{CDCl}_3$ :  $\delta = 77.16$  ppm). High Resolution Mass measurement was performed on Agilent Q-TOF 6520 mass spectrometer with electron spray ionization (ESI) as the ion source. Melting point (m.p.) was measured on a microscopic melting point apparatus.

## 2. General Procedure for the Preparation of Starting Materials

### 2.1 Preparation of 1-arylpyrazolidin-3-ones

Phenidones substrates were synthesized from the corresponding phenylhydrazine hydrochloride as shown in Scheme S1.



Scheme S1. Preparation of 1-arylpyrazolidin-3-ones


**1a, 1b, 1d** are commercially available, other phenidones were synthesized following a literature procedure.<sup>[1]</sup> To a solution of substituted phenylhydrazine hydrochloride (5.0 mmol, 1.0 equiv.) in dry pyridine (25 mL, 0.5 M), then 3-chloro-2,2-dimethylpropionyl chloride (5.0 mmol, 1.0 equiv.) were added at 0 °C. The reaction was allowed to warm to room temperature in 4 hours and was heated to 100 °C for 8 hours. The mixture was cooled, diluted using 30 mL DCM, and neutralized to pH 2 using aqueous HCl (1 M). Then the combined organic phases were washed with brine and

<sup>1</sup> C. F. H. Allen, J. R. Jr. Byers, US2772282, 1956.

dried over anhydrous  $\text{Na}_2\text{SO}_4$ . The solvent was removed to give the crude product which was purified by flash column chromatography to afford the desired compounds.

## 2.2 Preparation of Diazo Substrates


Diazo substrates were synthesized from the corresponding ketonic esters or 1,3 di-ketone as shown in Scheme S2.



**Scheme S2. Preparation of Diazo Substrates**

To a solution of ketonic ester or 1,3 di-ketone (5.0 mmol, 1.0 equiv.) in  $\text{CH}_3\text{CN}$  (10 mL),  $\text{TsN}_3$  (6.0 mmol, 1.1 equiv.) was added. Then the reaction mixture was cooled to 0 °C and a solution of DBU (6.0 mmol, 1.1 equiv.) in 10 mL  $\text{CH}_3\text{CN}$  was added dropwise. Next, the reaction temperature was raised to room temperature. After stirring for 3 hours, the residue was extracted with EA for three times. The combined organic layers were washed with water and brine sequentially, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The crude product was purified by flash chromatography on silica gel to afford the corresponding product in 70-90% yields.

## 3. Experimental Procedures



**Scheme S3. Synthesis of Pyrazolo[1,2-a]cinnolinines**

### 3.1 General Procedures

A sealed tube was charged with phenidone substrate **1** (0.2 mmol, 1.0 equiv.),  $(\text{RhCp}^*\text{Cl}_2)_2$  (0.01 mmol, 5.0 mol%),  $\text{AgSbF}_6$  (0.02 mmol, 0.1 equiv.), diazo **2** (0.32 mmol, 1.6 equiv.), 3 mL DCE. The reaction mixture was vigorously stirred at 40 °C (oil temperature) for 12 hours. After cooling to room temperature, the reaction mixture was diluted with EA (10 mL) and filtered through a plug of celite. The mixture was concentrated in *vacuo* and purified by flash chromatography on silica gel to afford the desired product **3**.

### 3.2 Additional Condition Screening

Following the general procedure for Rh-catalyzed intramolecular coupling between pyrazolidinone and diazo compounds, additional condition screening of different additives, precatalyst to silver salt ratios and solvent are shown below.

**Table S1. Screening of additives**

1a 1.0 equiv.	2a 1.6 equiv.	[Cp*RhCl <sub>2</sub> ] <sub>2</sub> (5.0 mol%) additives (10.0 mol%) DCE, 40 °C, air, 12 h	3aa
1		AgNTf <sub>2</sub>	68
2		AgSbF <sub>6</sub>	84
3		AgBF <sub>4</sub>	59
4		AgOTf	50
5		AgOAc	trace
6		CsOAc	0
7		NaOAc	0
8		HOAc	0
9		PivOH	0

<sup>a</sup>Isolated yields

**Table S2. Screening [Rh]/Ag ratio**

1a 1.0 equiv.	2a 1.6 equiv.	[Cp*RhCl <sub>2</sub> ] <sub>2</sub> (5.0 mol%) AgSbF <sub>6</sub> (y mol%) DCE, 40 °C, air, 12 h	3aa
1		0%	0
2		5%	<5
3		7%	50
4		9%	75
5		10%	84
6		13%	78
7		15%	74
8		20%	70
9 <sup>b</sup>		5%	80

<sup>a</sup>Isolated yields. <sup>b</sup>2.5 mmol% [Cp\*RhCl<sub>2</sub>]<sub>2</sub>) was used.

**Table S3. Screening solvent**




entry	solvent	yield (%) <sup>a</sup>
1	toluene	45
2	DCM	73
3	THF	49
4	EA	43
5	1,4-dioxane	20
6	acetone	41
7	$\text{CH}_3\text{CN}$	35
8	DMSO	0
9	${}^t\text{AmylOH}$	<5
10	methanol	trace

<sup>a</sup>Isolated yields.


## 4. Characterization of the Titled Products

### *tert-butyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3aa)*




50.4 mg, 84% yield,  $R_f = 0.23$  (PE/EA = 6:1), yellow solid, m. p. 84 - 85 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.07 (m, 1H), 6.98 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.86 (m, 1H), 6.46 (dd,  $J = 8.0, 1.1$  Hz, 1H), 3.58 (t,  $J = 8.4$  Hz, 2H), 2.71 (t,  $J = 8.4$  Hz, 2H), 2.40 (s, 3H), 1.57 (s, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 166.9, 165.7, 146.5, 137.5, 128.7, 123.4, 122.8, 122.4, 118.3, 111.0, 82.2, 46.6, 31.7, 28.2, 15.8, 15.8 ppm. IR (KBr): 3455, 1702, 1639, 1400, 1367, 1332, 1224, 1158, 748, 619 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 323.1372; Found 323.1366.

### *tert-butyl 2,5-dimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ba)*




46.5 mg, 74% yield,  $R_f = 0.25$  (PE/EA = 6:1), yellow oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.98 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.90 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.76 (td,  $J = 7.6, 1.2$  Hz, 1H), 6.39 (dd,  $J = 7.9, 1.1$  Hz, 1H), 3.81 (t,  $J = 9.1$  Hz, 1H), 2.95 (dd,  $J = 10.9, 9.4$  Hz, 1H), 2.74 (m, 1H), 2.33 (s, 3H), 1.49 (s, 9H), 1.20 (t,  $J = 7.5$  Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.6, 165.8, 146.4, 137.5, 128.7, 123.4, 122.8, 122.3, 118.0, 111.1, 82.2, 54.2, 37.1, 28.2, 15.8, 13.9 ppm. IR (KBr): 3453, 2976, 1706, 1637, 1492, 1452, 1382, 1368, 1334, 1227, 1161, 1146, 1015, 983, 845, 749, 685 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 337.1528; Found 337.1518.

### *tert-butyl 2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ca)*




49.9 mg, 76% yield,  $R_f = 0.24$  (PE/EA = 6:1), yellow oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.06 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.97 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.84 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.44 (dd,  $J = 8.0, 1.1$  Hz, 1H), 3.34 (s, 2H), 2.40 (s, 3H), 1.57 (s, 9H), 1.28 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 172.0, 165.8, 146.5, 137.4, 128.6, 123.4, 122.7, 122.2, 117.9, 111.0, 82.2, 60.2, 41.4, 28.2, 23.1, 15.7 ppm. IR (KBr): 3435, 2974, 2931, 1718, 1624, 1493, 1452, 1389, 1368, 1334, 1275, 1227, 1152, 1016, 983, 843, 778, 749, 699, 655 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 351.1685; Found 351.1677.

### *tert-butyl 2-(hydroxymethyl)-2,5-dimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3da)*




56.4 mg, 82% yield,  $R_f = 0.20$  (PE/EA = 3:1), yellow oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.00 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.88 (dd,  $J = 7.6, 1.5$  Hz, 1H), 6.77 (td,  $J = 7.5, 1.0$  Hz, 1H), 6.40 (d,  $J = 7.8$  Hz, 1H), 3.71 (dd,  $J = 11.1, 6.4$  Hz, 1H), 3.60 – 3.43 (m, 2H), 3.29 (d,  $J = 9.5$  Hz, 1H), 2.74 (t,  $J = 6.0$  Hz, 1H), 2.31 (s, 3H), 1.50 (s, 9H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.3, 165.7, 146.5, 136.7, 128.9, 123.4, 122.7, 122.0, 118.8, 111.2, 82.5, 65.4, 55.5, 47.2, 28.2, 18.9, 15.8 ppm. IR (KBr): 3449, 2924, 1701, 1452, 1399, 1335, 1229, 1153, 1051, 1017, 843, 748 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>NaO<sub>4</sub><sup>+</sup> 367.1634; Found 367.1629.

**tert-butyl 2,2,5,8-tetramethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ea)**




53.4 mg, 78% yield,  $R_f = 0.35$  (PE/EA = 6:1), yellow solid, m. p. 63 - 64 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.88 (d,  $J = 8.1$  Hz, 1H), 6.81 (s, 1H), 6.37 (d,  $J = 8.0$  Hz, 1H), 3.33 (s, 2H), 2.41 (s, 3H), 2.22 (s, 3H), 1.59 (d,  $J = 1.5$  Hz, 9H), 1.29 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 172.1, 165.9, 144.2, 137.3, 132.0, 128.8, 124.2, 122.1, 118.0, 111.0, 82.2, 60.4, 41.4, 28.2, 23.1, 20.8, 15.8 ppm. IR (KBr): 3435, 2973, 2930, 1705, 1629, 1499, 1459, 1389, 1368, 1333, 1273, 1236, 1151, 1025, 846, 807, 723, 675, 574 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>26</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 365.1841; Found 365.1834.

**tert-butyl 8-methoxy-2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3fa)**




53.7 mg, 75% yield,  $R_f = 0.30$  (PE/EA = 6:1), yellow solid, m. p. 90 - 91 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.65 (d,  $J = 2.7$  Hz, 1H), 6.60 (dd,  $J = 8.6, 2.8$  Hz, 1H), 6.39 (d,  $J = 8.6$  Hz, 1H), 3.73 (s, 3H), 3.31 (s, 2H), 2.42 (s, 3H), 1.58 (s, 9H), 1.28 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 172.2, 165.7, 155.4, 140.0, 138.4, 123.5, 117.5, 112.4, 111.9, 110.3, 82.2, 60.6, 55.5, 41.5, 28.2, 23.1, 15.7 ppm. IR (KBr): 3467, 2973, 2932, 1718, 1612, 1498, 1461, 1389, 1368, 1335, 1217, 1151, 1069, 1036, 845, 804, 724, 679, 592 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>26</sub>N<sub>2</sub>NaO<sub>4</sub><sup>+</sup> 381.1790; Found 381.1785.

**tert-butyl 2,2,5-trimethyl-8-nitro-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ga)**




32.8 mg, 44% yield,  $R_f = 0.33$  (PE/EA = 3:1), red solid, m. p. 168 - 169 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.93 (dd,  $J = 8.8, 2.5$  Hz, 1H), 7.82 (d,  $J = 2.5$  Hz, 1H), 6.36 (d,  $J = 8.8$  Hz, 1H), 3.40 (s, 2H), 2.42 (s, 3H), 1.60 (s, 9H), 1.31 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 171.5, 164.6, 151.5, 142.4, 140.4, 125.2, 122.3, 118.6, 115.4, 109.6, 83.2, 59.2, 41.2, 28.2, 23.2, 15.9 ppm. IR (KBr): 3449, 2974, 2921, 1720, 1708, 1655, 1638, 1580, 1512, 1396, 1333, 1305, 1227, 1149, 1095, 833, 751, 600 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup> 374.1716; Found 374.1713.

**tert-butyl 8-fluoro-2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ha)**




45.0 mg, 65% yield,  $R_f = 0.31$  (PE/EA = 6:1), red oil; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.96 – 6.54 (m, 2H), 6.38 (dd,  $J = 8.8, 4.6$  Hz, 1H), 3.32 (d,  $J = 1.4$  Hz, 2H), 2.44 (s, 3H), 1.59 (s, 9H), 1.29 (d,  $J = 1.5$  Hz, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 172.2, 165.3, 157.0, 142.5, 139.8, 124.1, 124.1, 116.6, 114.2, 113.9, 111.9, 111.8, 111.2, 110.9, 82.5, 60.4, 41.5, 28.2, 23.1, 15.8 ppm. IR (KBr): 3467, 2975, 2932, 1706, 1618, 1494, 1421, 1368, 1332, 1273, 1234, 1149, 1018, 845, 799, 724, 678 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 369.1590; Found 369.1582.

***tert-butyl 8-chloro-2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ia)***




47.0 mg, 65% yield,  $R_f = 0.34$  (PE/EA = 6:1), yellow solid, m. p. 68 - 69 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) δ 7.01 (m, 2H), 6.56 – 6.07 (m, 1H), 3.31 (d,  $J = 1.5$  Hz, 2H), 2.42 (s, 3H), 1.59 (s, 9H), 1.29 (d,  $J = 1.4$  Hz, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) δ 172.1, 165.2, 145.0, 139.6, 128.0, 127.9, 123.9, 123.5, 116.5, 112.1, 82.6, 60.1, 41.4, 28.2, 23.1, 15.8 ppm. IR (KBr): 3460, 2975, 1707, 1618, 1489, 1460, 1403, 1330, 1272, 1226, 1151, 1063, 1018, 968, 845, 806, 724, 674  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{19}\text{H}_{23}\text{ClN}_2\text{NaO}_3^+$  385.1295; Found 385.1288.

***tert-butyl 8-bromo-2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ja)***




56.0 mg, 69% yield,  $R_f = 0.33$  (PE/EA = 6:1), yellow solid, m. p. 65 - 66 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) δ 7.20 – 7.06 (m, 2H), 6.30 (d,  $J = 8.3$  Hz, 1H), 3.30 (d,  $J = 1.6$  Hz, 2H), 2.42 (s, 3H), 1.58 (s, 9H), 1.28 (d,  $J = 1.6$  Hz, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) δ 172.0, 165.2, 145.5, 139.6, 130.9, 126.3, 124.3, 116.3, 115.4, 112.4, 82.6, 60.0, 41.4, 28.2, 23.1, 15.8 ppm. IR (KBr): 3457, 2974, 1707, 1638, 1484, 1398, 1329, 1270, 1225, 1150, 1017, 844, 804, 663  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{19}\text{H}_{23}\text{BrN}_2\text{NaO}_3^+$  429.0790; Found 429.0785.

***tert-butyl 8-cyano-2,2,5-trimethyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ka)***




44.5 mg, 63% yield,  $R_f = 0.23$  (PE/EA = 5:1), yellow solid, m. p. 133 - 134 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) δ 7.43 – 7.25 (m, 1H), 7.20 (s, 1H), 6.40 (d,  $J = 8.3$  Hz, 1H), 3.36 (s, 2H), 2.42 (s, 3H), 1.60 (s, 9H), 1.31 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) δ 171.7, 164.8, 149.9, 140.1, 133.3, 126.3, 123.0, 115.6, 110.7, 105.4, 83.1, 59.3, 41.3, 28.2, 23.2, 15.9 ppm. IR (KBr): 3456, 2975, 2222, 1708, 1596, 1496, 1391, 1369, 1334, 1286, 1233, 1149, 1020, 887, 844, 814, 681  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{20}\text{H}_{23}\text{N}_3\text{NaO}_3^+$  376.1637; Found 376.1630.

***tert-butyl 2,2,5-trimethyl-3-oxo-8-(trifluoromethyl)-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3la)***




57.8 mg, 73% yield,  $R_f = 0.20$  (PE/EA = 6:1), yellow solid, m. p. 68 - 69 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) δ 7.47 – 7.11 (m, 2H), 6.45 (d,  $J = 8.3$  Hz, 1H), 3.36 (s, 2H), 2.44 (s, 3H), 1.58 (s, 9H), 1.29 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ ) δ 171.9, 165.0, 149.3, 140.1, 125.8, 125.7, 125.7, 124.7, 124.3, 122.7, 120.5, 120.4, 116.3, 110.5, 82.7, 59.7, 41.3, 28.1, 23.1, 15.8 ppm. IR (KBr): 3463, 2976, 1719, 1611, 1391, 1369, 1329, 1279, 1227, 1150, 1120, 1086, 1019, 842, 812, 654  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{20}\text{H}_{23}\text{F}_3\text{N}_2\text{NaO}_3^+$  419.1558; Found 419.1553.

*tert-butyl*      *2,2,5,9-tetramethyl-3-oxo-2,3-dihydro-1H-pyrazolo[1,2-a]cinnoline-6-carboxylate*  
*(3ma)*




39.7 mg, 58% yield,  $R_f = 0.25$  (PE/EA = 6:1), yellow solid, m. p. 94 - 95 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.87 (d,  $J = 7.8$  Hz, 1H), 6.66 (d,  $J = 7.8$  Hz, 1H), 6.29 (s, 1H), 3.35 (d,  $J = 1.4$  Hz, 2H), 2.40 (s, 3H), 2.26 (s, 3H), 1.57 (s, 9H), 1.29 (d,  $J = 1.5$  Hz, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 165.9, 146.6, 138.8, 136.4, 123.4, 123.1, 119.4, 118.1, 112.0, 82.1, 60.3, 41.4, 28.2, 23.1, 21.6, 15.7 ppm. IR (KBr): 3434, 2974, 1718, 1612, 1508, 1459, 1389, 1368, 1333, 1280, 1229, 1152, 1030, 991, 847, 812  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{20}\text{H}_{26}\text{N}_2\text{NaO}_3^+$  365.1841; Found 365.1829.

*tert-butyl*      *9-fluoro-2,2,5-trimethyl-3-oxo-2,3-dihydro-1H-pyrazolo[1,2-a]cinnoline-6-carboxylate* *(3na)*




39.7 mg, 49% yield,  $R_f = 0.26$  (PE/EA = 6:1), yellow solid, m. p. 150 - 151 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.05 (td,  $J = 8.4, 6.1$  Hz, 1H), 6.59 (t,  $J = 9.4$  Hz, 1H), 6.28 (d,  $J = 8.0$  Hz, 1H), 3.35 (s, 2H), 2.39 (s, 3), 1.55 (s, 9H), 1.29 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  172.0, 165.7, 158.6, 149.4, 138.4, 129.7, 129.6, 114.4, 110.6, 110.3, 106.9, 106.9, 82.1, 60.3, 41.4, 27.9, 23.1, 15.1 ppm. IR (KBr): 3464, 2977, 1712, 1697, 1612, 1583, 1469, 1392, 1340, 1249, 1237, 1154, 1094, 1028, 844, 792, 773, 734  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{19}\text{H}_{23}\text{FN}_2\text{NaO}_3^+$  369.1590; Found 369.1582.

*tert-butyl*      *2,2,5,10-tetramethyl-3-oxo-2,3-dihydro-1H-pyrazolo[1,2-a]cinnoline-6-carboxylate* *(3oa)*




48.6 mg, 71% yield,  $R_f = 0.23$  (PE/EA = 6:1), yellow solid, m. p. 48 - 49 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.86 (m, 1H), 6.83 - 6.71 (m, 2H), 3.61 (s, 2H), 2.37 (s, 3H), 2.29 (s, 3H), 1.56 (s, 9H), 1.27 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  171.6, 166.0, 147.9, 135.3, 133.1, 122.5, 122.1, 121.6, 121.6, 120.3, 82.2, 64.4, 40.2, 28.2, 22.7, 22.5, 16.1 ppm. IR (KBr): 3442, 2974, 1704, 1460, 1392, 1368, 1337, 1238, 1154, 1077, 1006, 846, 783, 739, 724  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{20}\text{H}_{26}\text{N}_2\text{NaO}_3^+$  365.1841; Found 365.1832.

*tert-butyl*      *8,10-difluoro-2,2,5-trimethyl-3-oxo-2,3-dihydro-1H-pyrazolo[1,2-a]cinnoline-6-carboxylate* *(3pa)*




58.3 mg, 80% yield,  $R_f = 0.26$  (PE/EA = 6:1), yellow solid, m. p. 80 - 81 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  6.87 - 6.01 (m, 2H), 3.64 (dd,  $J = 4.6, 1.4$  Hz, 2H), 2.41 (s, 3H), 1.57 (m, 9H), 1.26 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  172.2, 165.3, 160.4, 157.2, 142.5, 139.8, 124.2, 124.1, 116.6, 114.1, 113.8, 111.9, 111.8, 111.2, 110.9, 82.5, 60.4, 41.5, 28.2, 23.1, 15.7 ppm. IR (KBr): 3448, 2975, 2362, 1709, 1616, 1444, 1390, 1349, 1323, 1278, 1252, 1151, 1137, 996, 844, 683, 573  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{19}\text{H}_{22}\text{F}_2\text{N}_2\text{NaO}_3^+$  387.1496; Found 387.1497.

*methyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ab)*




40.8 mg, 79% yield,  $R_f = 0.21$  (PE/EA = 6:1), yellow solid, m. p. 94 - 95 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.09 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.98 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.86 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.49 (dd,  $J = 8.0, 1.2$  Hz, 1H), 3.86 (s, 3H), 3.60 (t,  $J = 8.4$  Hz, 2H), 2.74 (t,  $J = 8.4$  Hz, 2H), 2.43 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  167.1, 167.0, 146.6, 140.2, 128.8, 123.9, 122.9, 122.2, 116.3, 111.0, 52.0, 46.6, 31.7, 16.1 ppm. IR (KBr): 3450, 1720, 1707, 1655, 1630, 1492, 1400, 1366, 1330, 1209, 1031, 898, 751, 671, 643  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{14}\text{H}_{14}\text{N}_2\text{NaO}_3^+$  281.0902; Found 281.0894.

*ethyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ac)*




43.5 mg, 80% yield,  $R_f = 0.22$  (PE/EA = 6:1), yellow solid, m. p. 47 - 48 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.08 (td,  $J = 7.7, 1.5$  Hz, 1H), 7.00 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.85 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.57 – 6.39 (m, 1H), 4.34 (q,  $J = 7.1$  Hz, 2H), 3.59 (t,  $J = 8.4$  Hz, 2H), 2.73 (t,  $J = 8.4$  Hz, 2H), 2.43 (s, 3H), 1.36 (t,  $J = 7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  167.1, 166.5, 146.5, 139.5, 128.8, 123.7, 122.8, 122.2, 116.7, 111.0, 61.2, 46.6, 31.7, 16.0, 14.2 ppm. IR (KBr): 3458, 2980, 1707, 1620, 1451, 1360, 1330, 1205, 1098, 1032, 899, 751, 643  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{15}\text{H}_{16}\text{N}_2\text{NaO}_3^+$  295.1059; Found 295.1055.

*isopropyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ad)*




47.5 mg, 83% yield,  $R_f = 0.25$  (PE/EA = 6:1), yellow solid, m. p. 90 - 91 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.08 (t,  $J = 7.7$  Hz, 1H), 7.03 – 6.96 (m, 1H), 6.85 (t,  $J = 7.6$  Hz, 1H), 6.48 (d,  $J = 8.0$  Hz, 1H), 5.42 – 4.98 (m, 1H), 3.59 (t,  $J = 8.4$  Hz, 2H), 2.72 (t,  $J = 8.4$  Hz, 2H), 2.42 (s, 3H), 1.34 (d,  $J = 6.3$  Hz, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  167.0, 166.0, 146.5, 138.9, 128.8, 123.6, 122.8, 122.3, 117.1, 111.0, 69.0, 46.6, 31.7, 21.8, 16.0 ppm. IR (KBr): 3457, 2980, 1705, 1631, 1453, 1376, 1352, 1336, 1276, 1214, 1176, 1104, 1030, 900, 744, 670  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{16}\text{H}_{18}\text{N}_2\text{NaO}_3^+$  309.1215; Found 309.1209.

*benzyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ae)*




56.1 mg, 84% yield,  $R_f = 0.22$  (PE/EA = 6:1), yellow solid, m. p. 83 - 84 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.48 – 7.26 (m, 5H), 7.13 – 6.99 (m, 1H), 6.95 (d,  $J = 7.5$  Hz, 1H), 6.80 (t,  $J = 7.6$  Hz, 1H), 6.44 (d,  $J = 8.0$  Hz, 1H), 5.30 (s, 2H), 3.54 (t,  $J = 8.3$  Hz, 2H), 2.69 (t,  $J = 8.3$  Hz, 2H), 2.40 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  167.1, 166.3, 146.5, 140.2, 135.4, 128.8, 128.7, 128.6, 128.5, 123.8, 122.9, 122.2, 116.2, 111.1, 67.0, 46.6, 31.7, 16.2 ppm. IR (KBr): 3448, 1706, 1619, 1492, 1451, 1361, 1329, 1196, 1138, 1028, 895, 749, 695  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for  $\text{C}_{20}\text{H}_{18}\text{N}_2\text{NaO}_3^+$  357.1215; Found 357.1207.

*allyl 5-methyl-3-oxo-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3af)*




43.2 mg, 76% yield,  $R_f = 0.33$  (PE/EA = 6:1), red solid, m. p. 49 - 50 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.09 (td,  $J = 7.8, 1.5$  Hz, 1H), 7.01 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.86 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.49 (dd,  $J = 8.0, 1.2$  Hz, 1H), 6.21 – 5.85 (m, 1H), 5.55 – 5.14 (m, 2H), 4.77 (dt,  $J = 5.8, 1.4$  Hz, 2H), 3.60 (t,  $J = 8.4$  Hz, 2H), 2.74 (t,  $J = 8.4$  Hz, 2H), 2.44 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.1, 166.2, 146.6, 140.2, 131.6, 128.8, 123.9, 122.9, 122.2, 119.2, 116.3, 111.1, 65.8, 46.6, 31.7, 16.2 ppm. IR (KBr): 3434, 1707, 1618, 1580, 1493, 1451, 1357, 1328, 1273, 1199, 1029, 992, 935, 751, 672, 643, 567, 542 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 307.1059; Found 307.1050.

*ethyl 3-oxo-5-propyl-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ag)*




48.6 mg, 81% yield,  $R_f = 0.25$  (PE/EA = 6:1), yellow solid, m. p. 59 - 60 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.16 – 6.93 (m, 2H), 6.87 (m, 1H), 6.52 (dd,  $J = 8.0, 1.2$  Hz, 1H), 4.34 (q,  $J = 7.1$  Hz, 2H), 3.65 (t,  $J = 8.4$  Hz, 2H), 2.91 – 2.79 (m, 2H), 2.73 (t,  $J = 8.3$  Hz, 2H), 1.79 – 1.51 (m, 2H), 1.36 (t,  $J = 7.1$  Hz, 3H), 0.99 (t,  $J = 7.4$  Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 166.9, 166.5, 146.6, 142.9, 128.9, 123.8, 122.8, 122.2, 117.5, 111.0, 61.2, 46.3, 31.7, 30.3, 22.2, 14.2, 13.7 ppm. IR (KBr): 3462, 2962, 1707, 1629, 1451, 1361, 1338, 1241, 1200, 1026, 910, 750, 568 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>3</sub><sup>+</sup> 323.1372; Found 323.1366.

*ethyl 3-oxo-5-phenyl-2,3-dihydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (3ah)*




42.1 mg, 63% yield,  $R_f = 0.33$  (PE/EA = 3:1), red solid, m. p. 79 - 80 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (dd,  $J = 7.8, 1.5$  Hz, 1H), 7.50 – 7.28 (m, 5H), 7.20 (td,  $J = 7.8, 1.5$  Hz, 1H), 6.96 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.69 (dd,  $J = 8.1, 1.1$  Hz, 1H), 3.98 (q,  $J = 7.1$  Hz, 2H), 3.89 (t,  $J = 8.1$  Hz, 2H), 2.69 (t,  $J = 8.1$  Hz, 2H), 0.87 (t,  $J = 7.1$  Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.3, 166.0, 146.1, 139.4, 132.5, 129.5, 128.4, 128.2, 124.5, 123.0, 122.6, 119.4, 111.2, 61.1, 45.7, 31.0, 13.5 ppm. IR (KBr): 3456, 2921, 1711, 1481, 1450, 1340, 1206, 1022, 919, 857, 754, 698, 547 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 335.1396; Found 335.1384.

*6-acetyl-5-methyl-1,2-dihydro-3*H*-pyrazolo[1,2-*a*]cinnolin-3-one (3ai)*




25.2 mg, 52% yield,  $R_f = 0.35$  (PE/EA = 6:1), brown solid, m. p. 82 - 83 °C; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.12 (td,  $J = 7.7, 1.4$  Hz, 1H), 6.87 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.70 (dd,  $J = 7.6, 1.4$  Hz, 1H), 6.53 (dd,  $J = 8.0, 1.2$  Hz, 1H), 3.62 (t,  $J = 8.4$  Hz, 2H), 2.76 (t,  $J = 8.4$  Hz, 2H), 2.41 (s, 3H), 2.33 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 202.2, 167.0, 147.1, 135.9, 129.0, 124.7, 123.2, 123.0, 122.3, 111.3, 46.7, 31.7, 31.5, 15.7 ppm. IR (KBr): 3467, 2914, 1708, 1619, 1492, 1451, 1357, 1324, 1271, 1190, 1022, 960, 754, 559 cm<sup>-1</sup>. HRMS (ESI-TOF) m/z: [M + Na]<sup>+</sup> Calcd for C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>NaO<sub>2</sub><sup>+</sup> 265.0953; Found 265.0950.

**6-benzoyl-5-methyl-1*H*-pyrazolo[1,2-*a*]cinnolin-3(2*H*)-one (3aj)**




27.4 mg, 45% yield,  $R_f = 0.35$  (PE/EA = 3:1), red solid, m. p. 131–132 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.05 – 7.87 (m, 2H), 7.59 – 7.44 (m, 1H), 7.45 – 7.30 (m, 2H), 6.98 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.71 – 6.55 (m, 1H), 6.50 – 6.38 (m, 2H), 3.59 (t,  $J = 8.4$  Hz, 2H), 2.72 (t,  $J = 8.4$  Hz, 2H), 2.13 (s, 3H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  195.4, 166.6, 146.3, 136.8, 135.6, 134.1, 129.6, 129.0, 128.9, 123.6, 122.9, 111.1, 77.5, 77.1, 76.6, 46.8, 31.8, 16.3. IR (KBr): 3475, 3413, 1712, 1662, 1616, 1496, 1449, 1401, 1368, 1326, 1224, 1177, 999, 964, 904, 756, 705, 670, 635, 568  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + H] $^+$  Calcd for  $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_2^+$  305.1290; Found 305.1290

**11,11-dimethyl-2,3,11,12-tetrahydro-1*H*-benzo[c]pyrazolo[1,2-*a*]cinnoline-1,9(10*H*)-dione (3ak)**



38.4 mg, 68% yield,  $R_f = 0.23$  (PE/EA = 3:1), red solid, m. p. 170 – 171 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.05 (dd,  $J = 7.8, 1.5$  Hz, 1H), 7.12 (td,  $J = 7.7, 1.5$  Hz, 1H), 6.94 (td,  $J = 7.7, 1.2$  Hz, 1H), 6.49 (dd,  $J = 8.0, 1.2$  Hz, 1H), 3.60 (t,  $J = 8.3$  Hz, 2H), 3.05 (s, 2H), 2.82 (t,  $J = 8.3$  Hz, 2H), 2.38 (s, 2H), 1.13 (s, 6H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  195.9, 167.7, 151.2, 146.4, 128.6, 126.2, 123.2, 121.0, 115.1, 111.0, 52.0, 47.2, 38.6, 32.2, 32.0, 28.3 ppm. IR (KBr): 3484, 2956, 2914, 1718, 1654, 1595, 1362, 1309, 1259, 1196, 1147, 1113, 901, 753, 545  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + H] $^+$  Calcd for  $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_2^+$  283.1447; Found 283.1442.


**11-phenyl-2,3,11,12-tetrahydro-1*H*-benzo[c]pyrazolo[1,2-*a*]cinnoline-1,9(10*H*)-dione (3al)**



35.7 mg, 54% yield,  $R_f = 0.22$  (PE/EA = 3:1), red solid, m. p. 168 – 169 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.11 (d,  $J = 7.7$  Hz, 1H), 7.50 – 7.22 (m, 5H), 7.16 (t,  $J = 7.7$  Hz, 1H), 6.99 (t,  $J = 7.7$  Hz, 1H), 6.52 (d,  $J = 8.0$  Hz, 1H), 3.90 (dd,  $J = 19.0, 4.5$  Hz, 1H), 3.60 (m, 2H), 3.38 (m, 1H), 2.97 (m, 1H), 2.87 – 2.73 (m, 4H).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  195.0, 167.9, 152.3, 146.4, 142.3, 128.8, 128.8, 127.2, 126.8, 126.4, 123.4, 121.0, 115.8, 111.1, 47.1, 45.0, 38.6, 32.6, 32.0 ppm. IR (KBr): 3465, 2384, 1720, 1655, 1561, 1491, 1449, 1400, 1354, 1254, 1186, 1142, 904, 754, 700, 626  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + H] $^+$  Calcd for  $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_2^+$  331.1447; Found 331.1439.

## 5. Gram-scale Experiment and Further Transformations of Pyrazolo[1,2-a]cinnoline 3aa


### 5.1 A gram scale experiment of 3aa



Scheme S4. Gram-Scale Synthesis

A sealed tube was charged with 1-phenylpyrazolidin-3-one **1a** (5.0 mmol, 811 mg), ( $\text{RhCp}^*\text{Cl}_2$ )<sub>2</sub> (0.125 mmol, 75 mg),  $\text{AgSbF}_6$  (0.25 mmol, 88 mg), tert-butyl 2-diazo-3-oxobutanoate **2a** (8.0 mmol, 1.47g), 75 mL DCE. The reaction mixture was vigorously stirred at 40 °C (oil temperature) for 12 hours. After cooling to room temperature, the reaction mixture was diluted with EA (250 mL) and filtered through a plug of celite. The mixture was concentrated in *vacuo* and purified by flash chromatography on silica gel to afford the desired product **3aa** (1.24 g, 82% yield).

### 5.2 Further Transformations of 3aa




Scheme S5. Synthesis of the thioamide

A solution of **3aa** (60.0 mg, 0.2 mmol) and Lawesson reagent (60.6 mg, 0.15 mmol) in toluene (2.0 mL) was stirred and refluxed. After 12 hours, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford **4** in 60% yield.

#### *tert*-butyl 5-methyl-3-thioxo-2,3-dihydro-1*H*-pyrazolo[1,2-a]cinnoline-6-carboxylate (4)



**3aa** 37.9 mg, 60% yield,  $R_f = 0.23$  (PE/EA = 5:1), red solid, m. p. 106 - 107 °C; <sup>1</sup>H NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.17 (td,  $J = 7.7, 1.5$  Hz, 1H), 7.08 (dd,  $J = 7.7, 1.5$  Hz, 1H), 6.93 (td,  $J = 7.6, 1.1$  Hz, 1H), 6.66 – 6.52 (m, 1H), 3.78 (t,  $J = 8.7$  Hz, 2H), 3.27 (t,  $J = 8.7$  Hz, 2H), 2.68 (s, 3H), 1.59 (s, 9H). <sup>13</sup>C NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  165.2, 146.5, 136.7, 129.5, 125.6, 124.5, 122.7, 121.2, 110.8, 83.1, 47.7, 45.0, 28.2, 18.0 ppm. IR (KBr): 3467, 2976, 2929, 1716, 1629, 1597, 1453, 1400, 1368, 1316, 1272, 1233, 1154, 1126, 1063, 1021, 975, 841, 748, 646  $\text{cm}^{-1}$ . HRMS (ESI-TOF) m/z: [M + H]<sup>+</sup> Calcd for  $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_2\text{S}^+$  317.1323; Found 317.1322.



**Scheme S6. Reduction of the C=C bond**

A solution of **3aa** (60.0 mg, 0.2 mmol) in MeOH (2.0 mL) was added with 10% Pd/C (10 mg) in one portion. The mixture is stirred at room temperature under H<sub>2</sub> balloon (1 atm) for 24 hours and passed through a pad of celite, eluted with MeOH (10 mL). The mixture was concentrated under reduced pressure in *vacuo*. The residue was purified by silica gel column chromatography to afford **5** in 85% yield.


**tert-butyl (5*R*,6*R*)-5-methyl-3-oxo-2,3,5,6-tetrahydro-1*H*-pyrazolo[1,2-*a*]cinnoline-6-carboxylate (5)**



**Scheme S7. Epoxidation reaction**


A solution of **3aa** (60.0 mg, 0.2 mmol) in  $\text{CDCl}_3$  (2 mL) was added m-CPBA (69.0 mg, 0.4 mmol) and the reaction mixture was stirred at room temperature for overnight. After completion of the reaction, the solvent was concentrated by evaporator in *vacuo*. The residue was purified by silica gel column chromatography to afford **6** in 60% yield.

*tert*-butyl-(1*aR*,10*bR*)-1*a*-methyl-3-oxo-4,5-dihydro-3*H*-oxireno[2,3-*c*]pyrazolo[1,2-*a*]cinnoline-10*b*(1*aH*)-carboxylate (6)




## 6. Mechanistic Experiments

### 6.1 Competitive Reaction




A sealed tube was charged with **1f** (0.2 mmol, 44 mg), **1g** (0.2 mmol, 47 mg),  $(\text{RhCp}^*\text{Cl}_2)_2$  (0.01 mmol, 5.0 mol%),  $\text{AgSbF}_6$  (0.02 mmol, 10.0 mol%), **2a** (0.2 mmol, 36.8 mg), 3 mL DCE. The reaction mixture was vigorously stirred at 40 °C (oil temperature). After cooling to room temperature, the reaction mixture was diluted with EA (20 mL) and filtered through a plug of celite. The mixture was concentrated in *vacuo* and the residue was purified by column chromatography to give **3fa** and **3ga**.

t	<b>3fa</b> Yield (%)	<b>3ga</b> Yield (%)	<b>3fa/3ga</b>
5 min	45	4	11.2
10 min	54	11	4.9
20 min	56	11	5.1
30 min	58	12	4.8
1 h	60	13	4.6
3 h	61	14	4.3
6 h	63	16	3.9
12 h	69	18	3.8




Scheme S8. Competitive Reaction

## 6.2 H/D exchange experiment




Scheme S9. H/D exchange experiment


A sealed tube was charged with **1c** (0.2 mmol, 38 mg), ( $\text{RhCp}^*\text{Cl}_2)_2$  (0.01 mmol, 5 mol%),  $\text{AgSbF}_6$  (0.02 mmol, 10 mol%), 3 mL DCE and 0.2 mL  $\text{D}_2\text{O}$ . The reaction mixture was vigorously stirred at 40 °C (oil temperature) for 12 hours. After cooling to room temperature, the reaction mixture was diluted with EA (20 mL) and filtered through a plug of celite. The mixture was concentrated in *vacuo* and the residue was purified by column chromatography to give provide **[D<sub>2</sub>]-1c**. The deuterated ratio was calculated from <sup>1</sup>H NMR analysis.




### 6.3 kinetic isotope effect




A sealed tube was charged with **1c** (0.2 mmol, 38 mg), **[D<sub>5</sub>]-1c** (0.2 mmol, 39 mg), ( $\text{RhCp}^*\text{Cl}_2$ )<sub>2</sub> (0.01 mmol, 5.0 mol%),  $\text{AgSbF}_6$  (0.02 mmol, 10.0 mol%), **2a** (0.32 mmol, 59 mg), 3 mL DCE. The reaction mixture was vigorously stirred at 40 °C (oil temperature) for 35 minutes. After cooling to room temperature, the reaction mixture was diluted with EA (20 mL) and filtered through a plug of celite. The mixture was concentrated in *vacuo* and the residue was purified by column chromatography. The  $k_H/k_D$  value was calculated from <sup>1</sup>H NMR analysis.





## 7. Copies of $^1\text{H}$ NMR and $^{13}\text{C}$ NMR Spectra of the Titled Compounds







**3ba**




**3ba**  
 $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz)








<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)





<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)





<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)















































<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)




<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)



7.4166  
 7.4094  
 7.3972  
 7.3884  
 7.3839  
 7.3610  
 7.3447  
 7.3364  
 7.3176  
 7.2977  
 7.2486  
 7.0789  
 7.0745  
 7.0505  
 7.0348  
 7.0248  
 6.9615  
 6.9364  
 6.8264  
 6.8010  
 6.7757  
 6.4568  
 6.4303



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)





167.088  
 166.348  
 146.528  
 140.163  
 135.365  
 128.813  
 128.660  
 128.558  
 128.490  
 123.832  
 122.877  
 122.228  
 116.346  
 111.062

77.590  
 77.167  
 76.743  
 67.004  
 46.575  
 31.716  
 16.181





<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)







<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)




**3af**



7.2694
7.1311
7.1261
7.1053
7.1003
7.0794
7.0746
7.0614
7.0566
7.0357
7.0308
7.0012
6.9750
6.8949
6.8809
6.8694
6.8656
6.8541
6.8440
6.8403
6.5337
6.5298
6.5070
6.5032



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)



166.922  
166.458

128.578  
123.826  
122.805  
122.212  
117.514  
111.035

77.511  
77.086  
76.662


61.199

-46.337

165.11  
164.88  
163.90  
162.65  
161.96  
161.40  
159.75  
159.48  
138.77  
138.09  
136.39  
134.02  
120.87  
101.76  
0.9930  
-0.9766  
-0.9683  
-0.9578




<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)




7.6027
7.5978
7.5767
7.5719
7.4406
7.4279
7.4192
7.4150
7.4025
7.3924
7.3834
7.3750
7.3694
7.3587
7.2576
7.2284
7.2237
7.2025
7.1976
7.1767
7.1716
6.9846
6.9808
6.9593
6.9554
6.9336
6.9299
6.7037
6.7000
6.6767
6.6730
4.0197
3.9059
3.9721
3.9484
3.9142
3.8873
3.8605
2.7122
2.6853
2.6588
0.8981
0.8744
0.8506



<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)





<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)








<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)




3ai










**3al**  
<sup>1</sup>H NMR ( $\text{CDCl}_3$ , 300 MHz)





-194.996



-167.921



~152.272  
~146.397  
~142.323  
128.831  
128.766  
127.177  
126.825  
126.371  
123.351  
121.034  
115.799  
111.091

7.543  
77.121  
76.697  
128.831  
128.766  
127.177  
126.825  
126.371  
123.351  
47.140  
44.987  
38.635  
32.269  
32.045

-115.799











<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)



<sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz)



## 8. HMBC analysis

We determined the regioselectivity from HMBC analysis. We found that the 5-methyl group of the product was weakly related to the carbonyl group, but strongly related to the carbon atoms at 5- and 6-positions. It indicated that the product was **3aj** rather than **3aj'**. The results are shown as below:

